Login / Signup

Randomized double-blind placebo-controlled study to evaluate the effect of long-acting mesalamine on postinfectious irritable bowel syndrome with diarrhea.

Ashok K TutejaDaniel T LeungJohn C FangNicholas J TalleyGregory J Stoddard
Published in: Neurogastroenterology and motility (2024)
In patients with PI-IBS, long-acting mesalamine demonstrated to be effective in reducing IBS symptoms and improving QOL.
Keyphrases
  • irritable bowel syndrome
  • double blind
  • placebo controlled
  • clinical trial
  • phase iii
  • phase ii
  • study protocol
  • open label